[Hyperhidrosis is a silent handicap]

Ugeskr Laeger. 2016 Feb 8;178(6):V04150291.
[Article in Danish]

Abstract

Hyperhidrosis affects 2.8% of the population and has severe negative influence on life quality. The disease is represented in many specialties but can unfortunately be incorrectly treated or not treated at all. Primary hyperhidrosis is the most common form. Secondary hyperhidrosis is most often excluded by a few anamnestic data. Botulinum toxin and anticholinergics are adequate treatment options when aluminium chloride is insufficient. This article describes the disease from the physician's as well as the patient's perspective. Furthermore, examination procedures and treatment procedures are presented.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use
  • Cholinergic Antagonists / administration & dosage
  • Cholinergic Antagonists / therapeutic use
  • Humans
  • Hyperhidrosis* / diagnosis
  • Hyperhidrosis* / etiology
  • Hyperhidrosis* / psychology
  • Hyperhidrosis* / therapy
  • Neurotoxins / administration & dosage
  • Neurotoxins / therapeutic use
  • Quality of Life
  • Sweating / physiology

Substances

  • Cholinergic Antagonists
  • Neurotoxins
  • Botulinum Toxins, Type A